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Abstract 
Review on t(11;22)(q13;q13), with data on clinics, 
and the genes involved. 
Keywords 
Acute myeloid leukemia; t(11;22)(q13;q13); 
HRASLS5; PHF21B 
Clinics and pathology 
Disease 
Myeloid hemopathies 
Epidemiology 
Five cases of myeloid hemopathies (myelodysplastic 
syndrome, acute promyelocytic leukemia, chronic 
myeloid leukemia, acute erythroleukemia, and acute 
monoblastic leukemia (FAB type M5b) in an 
unpublished case herein described) with 
t(11;22)(q13;q13). No molecular characterization 
was performed in four cases (Gibbons et al., 1994; 
Jennings et al., 1998; Mauritzson et al., 2001; 
Ramkumar et al., 2008). 
Clinics 
A 52-year-old woman seen because of fever and 
asthenia (present case, and 2 male and 2 female 
patients, aged 48, 69, 73). 
Cytology 
Bone marrow aspirate showing 23.5% of blasts 
CD33+, MPO+, CD117+, CD11c+ (present case). 
Evolution 
Complete remission was not achieved by 
chemotherapy. She received allogeneic 
hematopoietic stem cell transplantation 6 months 
following diagnosis and remained in complete 
remission 10 months after transplantation. 
Cytogenetics 
Note 
A normal 46,XX karyotype was found at diagnosis 
in the present case.  
The t(11;22)(q13;q13) was identified during 
evolution (6 months after diagnosis but before stem 
cell transplantation).  
It involves the HRASLS5 and PHF21B genes that 
have never been shown to form a fusion gene. 
RHG banding showing chromosomes 11 and 22 and the 
derivatives der(11) and der(22). 
Cytogenetics morphological 
t(11;22)(q13;q13) is identified by banding 
cytogenetics. 
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Cytogenetics molecular 
To determine the position of the breakpoints on 
chromosomes 11 and 22, BAC clones located in the 
bands of interest were used as probes in FISH 
experiments. Analysis with RP11-449A4, located at 
11q13.1, showed a split signal while RP11-660B16 
was translocated on chromosome 22. The breakpoint 
was mapped between positions 63184796 and 
63242850, in a 58 kb region that contains 14kb of the 
HRASLS5 (HRAS-like suppressor family, member 
5) gene [UCSC Genome Browser on Human Feb. 
2009 (GRCh37/hg19) Assembly]. Analysis with 
RP11-367O12, located at 22q13.31, showed a split 
signal that hybridized to both der(11) and der(22). 
This BAC clone contains the PHF21B (PHD finger 
protein 21B) gene. 
Genes involved and 
proteins 
HRASLS5 
Location 
11q13.2 
DNA/RNA 
The HRASLS5 gene contains 6 coding exons, 
spanning 29.8 kb. It is predominantly expressed in 
testis (Jin et al., 2009). 
Protein 
The protein has 279 amino acids and catalyzes the 
N-acylation of phosphatidylethanolamine (PE) to 
generate N-acylphosphatidylethanolamine (NAPE), 
a precursor of bioactive N-acylethanolamines. 
Mutagenesis studies suggested a possible role of the 
N-terminal domain in membrane association or 
protein-protein interaction (Jin et al., 2009). 
However, its function(s) remain(s) largely unknown. 
Whether HRASLS5 is a tumor suppressor involved 
in the control of cell proliferation as other members, 
notably HRASLS2, belonging to the same family, 
remains to be determined (Hughes et al., 2000; Shyu 
et al., 2008; Uyama et al., 2009). 
PHF21B 
Location 
22q13.31 
DNA/RNA 
The PHF21B gene contains 13 coding exons, 
spanning 127.8 kb, according to the UCSC Genome 
Browser, but 16 according to the National Center for 
Biotechnology Information (NCBI). There are 8 
probable alternative promoters and transcription  
produces 13 alternatively spliced mRNAs 
(http://www.ncbi.nlm.nih.gov/IEB/Research/Acem
bly/av.cgi?db=humanq=PHF21B). 
Protein 
The protein has 531 amino acids. It contains one 
PHD (homeodomain) type zinc finger domain 
(amino acids 313-357), found in nuclear proteins 
thought to be involved in chromatin-mediated 
transcriptional regulation, and a transcription 
initiation factor TFIIIB, Bdp1 subunit (amino acids 
137-267), involved in regulating transcription from 
RNA polymerase III promoters 
(http://www.ncbi.nlm.nih.gov/gene/112885). 
However, its function(s) remain(s) largely unknown. 
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